Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy.

Fiscus SA, Cu-Uvin S, Eshete AT, Hughes MD, Bao Y, Hosseinipour M, Grinsztejn B, Badal-Faesen S, Dragavon J, Coombs RW, Braun K, Moran L, Hakim J, Flanigan T, Kumarasamy N, Campbell TB; A5185s Team..

Clin Infect Dis. 2013 Jul;57(2):290-7. doi: 10.1093/cid/cit195.

2.

HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.

Sheth AN, Evans-Strickfaden T, Haaland R, Martin A, Gatcliffe C, Adesoye A, Omondi MW, Lupo LD, Danavall D, Easley K, Chen CY, Pau CP, Hart C, Ofotokun I.

J Infect Dis. 2014 Sep 1;210(5):736-44. doi: 10.1093/infdis/jiu166.

3.

Genital tract leukocytes and shedding of genital HIV type 1 RNA.

Anderson BL, Wang CC, Delong AK, Liu T, Kojic EM, Kurpewski J, Ingersoll J, Mayer K, Caliendo AM, Cu-Uvin S.

Clin Infect Dis. 2008 Nov 1;47(9):1216-21. doi: 10.1086/592303.

4.

Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA.

Graham SM, Jalalian-Lechak Z, Shafi J, Chohan V, Deya RW, Jaoko W, Mandaliya KN, Peshu NM, Overbaugh J, McClelland RS.

J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):511-8. doi: 10.1097/QAI.0b013e31825bd703.

5.

Cell-Associated HIV-1 DNA and RNA Decay Dynamics During Early Combination Antiretroviral Therapy in HIV-1-Infected Infants.

Uprety P, Chadwick EG, Rainwater-Lovett K, Ziemniak C, Luzuriaga K, Capparelli EV, Yenokyan G, Persaud D.

Clin Infect Dis. 2015 Dec 15;61(12):1862-70. doi: 10.1093/cid/civ688.

6.

Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy.

Péré H, Rascanu A, LeGoff J, Matta M, Bois F, Lortholary O, Leroy V, Launay O, Bélec L; ANRS EP24 study group..

Int J STD AIDS. 2016 Mar;27(3):178-85. doi: 10.1177/0956462415577727.

PMID:
25769886
7.

Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.

Cu-Uvin S, Caliendo AM, Reinert S, Chang A, Juliano-Remollino C, Flanigan TP, Mayer KH, Carpenter CC.

AIDS. 2000 Mar 10;14(4):415-21.

PMID:
10770544
8.

Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.

Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S; CNA3002 European Study Team..

HIV Med. 2001 Jan;2(1):27-34.

9.

Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study.

Low AJ, Konate I, Nagot N, Weiss HA, Kania D, Vickerman P, Segondy M, Mabey D, Pillay D, Meda N, van de Perre P, Mayaud P; Yerelon Study Group..

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):237-45. doi: 10.1097/QAI.0000000000000049.

10.

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C.

J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098.

11.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

12.

Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.

Chaix ML, Seng R, Frange P, Tran L, Avettand-Fenoël V, Ghosn J, Reynes J, Yazdanpanah Y, Raffi F, Goujard C, Rouzioux C, Meyer L; ANRS PRIMO Cohort Study Group..

Clin Infect Dis. 2013 Mar;56(6):880-7. doi: 10.1093/cid/cis999.

13.

Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.

Vettore MV, Schechter M, Melo MF, Boechat LJ, Barroso PF.

J Infect. 2006 Apr;52(4):290-3.

PMID:
16038980
14.

Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.

Scherrer AU, Ledergerber B, von Wyl V, Böni J, Yerly S, Klimkait T, Bürgisser P, Rauch A, Hirschel B, Cavassini M, Elzi L, Vernazza PL, Bernasconi E, Held L, Günthard HF; Swiss HIV Cohort Study..

Clin Infect Dis. 2011 Dec;53(11):1143-52. doi: 10.1093/cid/cir669.

15.

HIV-1 RNA levels and antiretroviral drug resistance in blood and non-blood compartments from HIV-1-infected men and women enrolled in AIDS clinical trials group study A5077.

Kantor R, Bettendorf D, Bosch RJ, Mann M, Katzenstein D, Cu-Uvin S, D'Aquila R, Frenkel L, Fiscus S, Coombs R; ACTG A5077 Study Team..

PLoS One. 2014 Apr 3;9(4):e93537. doi: 10.1371/journal.pone.0093537.

16.

HIV-1 drug resistance in variants from the female genital tract and plasma.

Kemal KS, Burger H, Mayers D, Anastos K, Foley B, Kitchen C, Huggins P, Schroeder T, Picchio G, Back S, Gao W, Meyer WA 3rd, Weiser B.

J Infect Dis. 2007 Feb 15;195(4):535-45.

17.

The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.

Di Biagio A, Rusconi S, Marzocchetti A, Signori A, Schiavetti I, Bruzzone B, Monno L, Punzi G, Colao MG, Penco G, Zazzi M, De Luca A; ARCA Collaborative Group..

J Med Virol. 2014 Oct;86(10):1648-55. doi: 10.1002/jmv.24017.

PMID:
25042976
18.

Impact of HIV-1 Subtype on the Time to CD4+ T-Cell Recovery in Combination Antiretroviral Therapy (cART)-Experienced Patients.

Chow WZ, Lim SH, Ong LY, Yong YK, Takebe Y, Kamarulzaman A, Tee KK.

PLoS One. 2015 Sep 3;10(9):e0137281. doi: 10.1371/journal.pone.0137281.

19.
20.

Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study.

Launay O, Tod M, Tschöpe I, Si-Mohamed A, Bélarbi L, Charpentier C, Goujard C, Taburet AM, Lortholary O, Leroy V, Bélec L; ANRS EP24 GYNODYN Study Group..

Antivir Ther. 2011;16(6):843-52. doi: 10.3851/IMP1856.

PMID:
21900716
Items per page

Supplemental Content

Support Center